The results of the Cancer Drugs Benefit Appraisal Committee were released from the 13th. The HIRA has accepted complaints continuously filed in the pharmaceutical industry.

Some point out that they are not satisfied yet, but it can be said that it is encouraging in itself because the HIRA expressed its intention to deliver the exact reason for the success at the request of the company. In the pharmaceutical industry, discussions on expanding insurance benefits for new drugs have been focused on the Cancer Drugs Benefit Appraisal Committee along with the COVID-19 incident.The Cancer Drugs Benefit Appraisal Committee, which was discussing the clinical usefulness of drugs, began examining the financial b